Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BL-M24D1 in HNSCC and Solid Tumors
NCT07232524Phase 1Recruiting
- Sponsor
- Biokin Pharmaceutical
- Start
- Dec 2025
- Primary completion
- Nov 2027
- Modality
- Antibody-Drug Conjugates (ADCs)
- Countries
- 1
01
Overview
Phase 1, open-label trial of BL-M24D1 in head and neck squamous cell carcinoma (HNSCC) and solid tumor, sponsored by Biokin Pharmaceutical. Primary endpoints: Dose Limiting Toxicity at 28 days, Maximum Tolerated Dose at 28 days and 1 more. Started Dec 2025; status: recruiting.
02
Drugs
BL-M24D1
03
Conditions
head and neck squamous cell carcinoma (HNSCC)solid tumor
Beyond the preview
Go deeper on NCT07232524.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07232524.